Why Deneb Medical's EIC Accelerator Spine Robot Has Yet to Launch

Deneb Medical has spent twelve years building a surgical robot that is meant to recognise the tissue in front of it before it cuts. The San Sebastián company was selected in the EIC SME Instrument Phase 2 cut-off of 3 April 2019, the Horizon 2020 programme that became the EIC Accelerator, and the European Commission's list of winners names it as the only company in the X-BONECUT project. The grant, an EU contribution of €2,103,193.40 towards a total cost of €3,098,377, paid for a robot to perform minimally invasive lumbar spine surgery "in a safe and fast way", according to CORDIS. The project ran from 1 November 2019 to 30 April 2022.

The robot now carries the name IZAR. In September 2026 Deneb Medical closed a €14.7 million round to bring it "to market", according to the company and the Spanish Ministry for Digital Transformation. That wording answers the question in the title: four and a half years after the EU project ended, the system has been tested on pigs and human cadavers, but no operation on a patient, clinical trial registration or CE mark has been made public.

Where Deneb Medical Stands Now

The company is active and better funded than at any point in its history. The September 2026 round brought €7.2 million from SETT, the Spanish state's technology investment company, €5 million from what Deneb Medical calls "a leading U.S. multinational in the development and commercialization of medical devices", and €2.5 million from Kutxa Fundazioa through its Bidelagun programme, according to the company's announcement of 8 September 2026. The government confirmed the SETT share and said the money came from its Next Tech facility, which is financed by the EU's NextGenerationEU recovery funds. When the minister Óscar López visited the company later that month, the ministry said the team of 22 was expected to grow to 90 by 2032, according to a second ministry release.

The commercial register records the same round. In August 2026 the share capital rose in two steps from €45,682 to €57,558, new articles introduced two classes of shares, Kutxa Fundazioa took a board seat on 11 August and Ori Hadomi joined the board on 12 August, according to BORME entries summarised by Empresia. Hadomi led Mazor Robotics, the Israeli spine robot maker, until Medtronic bought it for $1.64 billion in December 2018, and then joined Medtronic, according to biographies published by the Hamlyn Symposium and the Delphi Economic Forum, which names him "VP of strategic initiatives & partnerships at Medtronic". Neither Deneb Medical nor the government has named the US investor, and no source found for this article confirms who it is.

In May 2025 the founders stepped down as chairman and vice chairman in person and were replaced by their holding companies, Acorn Capital and Monolithus MMI, the register shows. The register summary on Infoempresa puts the company at 10 to 49 employees and annual turnover below €2 million. Accounts for 2020 to 2024 are filed, but the figures sit behind a paywall and were not reviewed for this article.

The Technology: A Robot That Checks the Tissue Before It Cuts

In spine surgery the bone over a compressed nerve is usually removed with drills and bone punches. The danger is the dura, the thin membrane around the spinal cord and nerve roots. In its first EU project, BoneCut, Deneb Medical said up to 10% of craniotomies and laminectomies end with an "incidental durotomy", an accidental tear of that membrane, according to its 2018 CORDIS report. Its answer is to remove bone with a laser held by a robot, with optical sensors and its own algorithms to tell bone from other tissue in real time, so that the robot stops before it reaches the dura.

The difference from established spine robots is the claim to autonomy. Systems such as Medtronic's Mazor, Zimmer's ROSA and Globus Medical's ExcelsiusGPS position instruments precisely, and the surgeon still does the cutting; Deneb Medical argues in its X-BONECUT final report that robots need "robotic eyes" to take decisions of their own. Today the company's website describes IZAR in four steps: planning, radiation-free registration of the patient in under two minutes, robot-guided insertion of pedicle screws, and laser decompression that it says is "25% faster than manual procedures". No peer-reviewed study comparing IZAR with manual surgery in patients was found to support that figure.

The only paper CORDIS lists from the project is a pilot study in minipigs comparing laser and drill bone cuts for lumbar laminotomy, by Deneb Medical engineers with surgeons from Vall d'Hebron and the University Hospital of San Sebastián, published in Lasers in Surgery & Medicine in 2022, according to the project results page. The same page lists five patent applications filed between 2018 and 2020, on tissue discrimination, polarisation-sensitive OCT and monitoring of the surgical scene, and a Spanish utility model for marking the path of a screw.

In September 2025 the company said a separate Spanish project, VILAROQ, had built an in-house swept-source OCT imaging system for IZAR with the firm Zepren, the Tekniker technology centre and the photonics cluster secpho, to reduce reliance on single commercial suppliers of OCT, according to Deneb Medical. The same release says only that "preclinical validations" of IZAR had shown gains in standardisation and surgical time.

What X-BONECUT Promised, and What CORDIS Shows

The project had three stated aims: turn the prototype into a product that meets medical device standards, run the preclinical trials that come before the first human cases, and define a market access strategy, according to the final CORDIS report. The report says Deneb Medical completed a final prototype and the disposable element under ISO 13485, ran trials on live minipigs at Specipig and on human cadavers at the Biodonostia Health Research Institute, and set up an ISO 13485 quality system checked by an internal audit. No certification of that quality system by a notified body is mentioned.

The report also lists clinical trials as a work item. It says the company "prepared the clinical test protocol" and "has been in contact" with hospitals and surgeons to run them, and it concludes that the work "has prepared Deneb for the next steps of clinical validation". No trial was run within the project. A search of ClinicalTrials.gov on 8 October 2026 returned no study sponsored by Deneb Medical, and none of the company's news items since 2022 reports a first patient. The company itself said in September 2022 that the COVID pandemic had "heavily impacted the performance of some tasks", while describing the project as "successfully completed". The project ended on its scheduled date of 30 April 2022.

1. Industrialised robot and disposable to device standardsDeliveredFinal prototype and disposable completed under ISO 13485, per the CORDIS report.
2. Preclinical trials before first human casesDeliveredMinipig and cadaver trials; minipig pilot study published in 2022.
3. Clinical trials in patientsNot achievedProtocol prepared only; no trial registered or announced by October 2026.
4. Market access strategy and industry partnerPartlyThe report cites an agreement with Medtronic whose terms are not public; a US medtech group invested in 2026.
5. Endoscopic lumbar robot on the marketNot yetThe 2026 round is raised to bring IZAR "to market"; no CE mark is public.

One claim in the report rests on the company's word alone. It says Deneb Medical signed "an agreement with Medtronic", which "had a great impact in consolidating the business and commercialization plans". Neither company has published the agreement, and no press coverage of it was found.

The Money Since the Award

Deneb Medical has been funded through a long chain of public grants and modest equity. Before the EIC award it received Neotec support from CDTI in 2015, Gipuzkoa provincial grants and a €50,000 SME Instrument Phase 1 grant for BoneCut in 2018, according to its news archive and CORDIS. In April 2019 it closed an equity round with Orza and the Basque public venture fund, and signed a CDTI loan, both without published amounts. CDTI's Innvierte programme invested €250,000 in April 2022, according to Capital Riesgo and the company. In December 2022 it raised "more than €2.5 million" from private investors and the Science Ministry's public-private partnership call, project CPP2021-008711, according to Deneb Medical. Basque Hazitek grants followed in 2023 and 2024.

The SME Instrument award was a grant only, with no equity from the EIC Fund, and the company does not appear in any EIC Fund announcement found for this article.

Why It Matters for Europe

The spine robots that Deneb Medical's own EU report names as the benchmark, Mazor, ROSA and ExcelsiusGPS, belong to Medtronic, Zimmer and Globus Medical. Deneb Medical is a European attempt to build a spine robot from its own optics up, and the VILAROQ project was framed explicitly as cutting dependence on single suppliers of OCT imaging. The Spanish state has now backed it with NextGenerationEU money on condition that the company keeps its headquarters in the Basque Country, the ministry says. The entry of a US medtech multinational, which Deneb Medical says will "facilitate the integration of the system into global surgical platforms", also means the route to market may run through an American partner.

The Verdict

Deneb Medical has not been asked for comment for this article. It is based on public records and published statements, linked throughout.